{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:50:12Z","timestamp":1784631012268,"version":"3.55.0"},"reference-count":35,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T00:00:00Z","timestamp":1537833600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7172106"],"award-info":[{"award-number":["7172106"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      B7\u2010H3 is attractive for cancer immunotherapy with B7\u2010H3 overexpressed tumors. To explore whether B7\u2010H3 is an effective target for patients with bladder cancer, anti\u2010\n                      <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                      3\u00d7 anti\u2010B7\u2010H3 bispecific antibodies (B7\u2010H3Bi\u2010Ab) was armed with activated T cells (\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      ) to kill bladder cancer cells.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      High expressions of B7\u2010H3 on human bladder cancer cells were detected, including Pumc\u201091 and T24 cells, and their chemotherapeutic drug\u2010resistant counterparts.\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      generated from healthy donors were stimulated with anti\u2010\n                      <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                      3 monoclonal antibody and interleukin\u20102 (\n                      <jats:styled-content style=\"fixed-case\">IL<\/jats:styled-content>\n                      \u20102) for 13\u00a0days. The ability of\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      armed with B7\u2010H3Bi\u2010Ab to kill bladder cancer cells was detected by flow cytometry,\n                      <jats:styled-content style=\"fixed-case\">LDH<\/jats:styled-content>\n                      , Elisa, and luciferase quantitative assay. Moreover,\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      generated from bladder cancer patients was armed with B7\u2010H3Bi\u2010Ab to verity the cell killing by the methods as previously described.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared with unarmed\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      , a significant increased cytotoxicity of B7\u2010H3Bi\u2010Ab\u2010armed\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      against bladder cancer cells was discovered. The B7\u2010H3Bi\u2010Ab\u2010armed\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      secreted more\n                      <jats:styled-content style=\"fixed-case\">IFN<\/jats:styled-content>\n                      \u2010\u03b3,\n                      <jats:styled-content style=\"fixed-case\">TNF<\/jats:styled-content>\n                      \u2010\u03b1, and expressed high levels of activation marker\n                      <jats:styled-content style=\"fixed-case\">CD<\/jats:styled-content>\n                      69. Interestingly, despite the presence of immunosuppression in patients and resistance in chemotherapeutic drug\u2010resistant cancer cell lines, B7\u2010H3Bi\u2010Ab\u2010armed\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      from patients with bladder cancer still showed significant cytotoxic activity against bladder cancer cells and their chemotherapeutic drug\u2010resistant counterparts.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      B7\u2010H3 is an effective target for bladder cancer. B7\u2010H3Bi\u2010Ab enhances the ability of\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      to kill bladder cancer cells. B7\u2010H3Bi\u2010Ab\u2010armed\n                      <jats:styled-content style=\"fixed-case\">ATC<\/jats:styled-content>\n                      is promisingly to provide a novel strategy for current bladder cancer therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.1775","type":"journal-article","created":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T12:02:06Z","timestamp":1537876926000},"page":"5167-5177","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Targeting immunotherapy for bladder cancer using anti\u2010\n                    <scp>CD<\/scp>\n                    3\u00d7 B7\u2010H3 bispecific antibody"],"prefix":"10.1002","volume":"7","author":[{"given":"Wanru","family":"Ma","sequence":"first","affiliation":[{"name":"Collage of Medical Technique Xuzhou Medical University  Jiangsu China"},{"name":"Department of Clinical Laboratory Medicine Beijing Shijitan Hospital Capital Medical University  Beijing China"},{"name":"Peking University Ninth School of Clinical Medical  Beijing China"},{"name":"Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine Beijing Shijitan Hospital Capital Medical University  Beijing China"},{"name":"Peking University Ninth School of Clinical Medical  Beijing China"},{"name":"Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Ma","sequence":"additional","affiliation":[{"name":"Collage of Medical Technique Xuzhou Medical University  Jiangsu China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine Beijing Shijitan Hospital Capital Medical University  Beijing China"},{"name":"Peking University Ninth School of Clinical Medical  Beijing China"},{"name":"Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine Beijing Shijitan Hospital Capital Medical University  Beijing China"},{"name":"Peking University Ninth School of Clinical Medical  Beijing China"},{"name":"Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-6804","authenticated-orcid":false,"given":"Man","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Medicine Beijing Shijitan Hospital Capital Medical University  Beijing China"},{"name":"Peking University Ninth School of Clinical Medical  Beijing China"},{"name":"Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,9,25]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2004.05.020"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199004193221607"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/00042307-199609000-00009"},{"key":"e_1_2_6_6_1","unstructured":"NCI Surveillance Epidemiology and End Results Program.Cancer of the Urinary Bladder\u2014SEER Stat Fact Sheets 2016.https:\/\/seer.cancer.gov\/statfacts\/html\/urinb.html. Accessed December 18 2016."},{"key":"e_1_2_6_7_1","unstructured":"American Cancer Society.Survival rates for bladder cancer 2016.http:\/\/www.cancer.org\/cancer\/bladdercancer\/detailedguide\/bladder-cancer-survival-rates. Accessed December 18 2016."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1744"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10673"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2017.06.014"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.03.005"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1179\/1607845414Y.0000000186"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2014.2268"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.3109\/07357907.2014.909826"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-014-3564-2"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1068"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-012-9885-3"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.114"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2012.1212"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.28474"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8784"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.17759"},{"key":"e_1_2_6_24_1","first-page":"70","article-title":"The establishment and biological characteristics evaluation of human multidrug\u2010resistant bladder cancer Pumc\u201091\/ADM cell line","volume":"38","author":"Zhang M","year":"2009","journal-title":"J Med Res"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2017.6111"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11434"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157759"},{"key":"e_1_2_6_28_1","first-page":"338","article-title":"Establishment of cisplatin\u2010multi drug resistance cell line of human bladder cancer T24 and its biological characteristics","volume":"22","author":"Zhao M","year":"2015","journal-title":"Immunoassays Clin Med"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0073261"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2014.2663"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2015.4233"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0011867"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2004.11.021"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12559"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2016.5288"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201646837"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcam4.1775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1775","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.1775","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.1775","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:02:49Z","timestamp":1781092969000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.1775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,25]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["10.1002\/cam4.1775"],"URL":"https:\/\/doi.org\/10.1002\/cam4.1775","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,25]]},"assertion":[{"value":"2018-04-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-09-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}